Aclaris Therapeutics Stock Investor Sentiment
| ACRS Stock | USD 1.57 0.02 1.29% |
Slightly above 61% of all Aclaris Therapeutics' private investors are looking to take a long position. The analysis of overall sentiment of trading Aclaris Therapeutics stock suggests that some investors are interested at this time. Aclaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Aclaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
Aclaris |
Aclaris Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Aclaris Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Aclaris Therapeutics that are available to investors today. That information is available publicly through Aclaris media outlets and privately through word of mouth or via Aclaris internal channels. However, regardless of the origin, that massive amount of Aclaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aclaris Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aclaris Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aclaris Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aclaris Therapeutics alpha.
Aclaris Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3 | 12/31/2024 |
2 | Disposition of 29149 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 73750 shares by James Loerop of Aclaris Therapeutics subject to Rule 16b-3 | 01/03/2025 |
4 | Acquisition by Leonard Braden Michael of 206025 shares of Aclaris Therapeutics at 1.2443 subject to Rule 16b-3 | 01/17/2025 |
5 | Aclaris Therapeutics Announces Formation of New Scientific Advisory Board | 01/30/2025 |
6 | Disposition of 11250 shares by James Loerop of Aclaris Therapeutics subject to Rule 16b-3 | 01/31/2025 |
7 | Acquisition by James Loerop of 83500 shares of Aclaris Therapeutics subject to Rule 16b-3 | 02/03/2025 |
8 | Disposition of 14750 shares by James Loerop of Aclaris Therapeutics subject to Rule 16b-3 | 02/04/2025 |
9 | New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ... | 02/12/2025 |
10 | Disposition of 73750 shares by Kevin Balthaser of Aclaris Therapeutics subject to Rule 16b-3 | 02/19/2025 |
11 | Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a ... | 02/27/2025 |
12 | Disposition of 50000 shares by Joseph Monahan of Aclaris Therapeutics subject to Rule 16b-3 | 02/28/2025 |
13 | JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50 Key Pharma Companies Actively Working in the Therapeutics Segment DelveInsight DelveInsight | 03/03/2025 |
14 | Aclaris Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags | 03/04/2025 |
15 | Aclaris Therapeutics, Inc. Shares May Have Slumped 27 percent But Getting In Cheap Is Still Unlikely | 03/07/2025 |
16 | Acquisition by Walker Neal of 9466 shares of Aclaris Therapeutics subject to Rule 16b-3 | 03/14/2025 |
17 | Aclaris Therapeutics Earns Overweight Rating from Analysts at Cantor Fitzgerald | 03/18/2025 |
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.